TY - JOUR T1 - The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors JF - Anticancer Research JO - Anticancer Res SP - 5117 LP - 5122 DO - 10.21873/anticanres.15328 VL - 41 IS - 10 AU - JOSEF VODICKA AU - MARTIN SKALA AU - JAKUB SEBEK AU - VLADISLAV TRESKA AU - JAKUB FICHTL AU - KRISTYNA PROCHAZKOVA AU - BOHUSLAVA VANKOVA AU - MARTIN SVATON AU - LADISLAV PECEN AU - ONDREJ TOPOLCAN AU - MONIKA BLUDOVSKA AU - RADEK KUCERA Y1 - 2021/10/01 UR - http://ar.iiarjournals.org/content/41/10/5117.abstract N2 - Aim: The aim of this study was to evaluate the utility of selected tumor markers for the detection of lung cancer recurrence during follow-up. Patients and Methods: The study group consisted of 109 patients and 109 healthy controls. The following biomarkers were selected: Carcinoembryonic antigen; cytokeratin fragment 19; neuron-specific enolase; tissue polypeptide-specific antigen; cytokeratin fragments 8, 18 and 19; insulin-like growth factor 1; pro-gastrin-releasing peptide; and 25-hydroxyvitamin D. The biomarkers were assessed individually or using a multivariate analysis. Results: Carcinoembryonic antigen [area under the receiver operating characteristics curve (AUC)=0.6857, p<0.0001] and cytokeratin fragment 19 (AUC=0.6882, p<0.0001) proved best in detecting relapse. The multivariate model indicated insulin-like growth factor 1 (p=0.0006, AUC=0.6225) as the third most useful biomarker. The multivariate model using these three markers achieved the best AUC value of 0.7730 (p=0.0050). Conclusion: We demonstrated that carcinoembryonic antigen and cytokeratin fragment 19 play a key role in the detection of lung cancer recurrence. A multivariate approach can increase the effectiveness of detection. ER -